St. Jude Children’s Research Hospital has reaffirmed its pivotal role in the global fight against pediatric cancer with its recent redesignation as a World Health Organization (WHO) Collaborating Centre for Childhood Cancer. This prestigious status not only honors St. Jude’s deep-rooted commitment to advancing pediatric oncology but also solidifies its unique position as the sole WHO Collaborating Centre exclusively dedicated to childhood cancer worldwide. The designation reflects the hospital’s substantial contributions in providing strategic, scientific, and technical expertise to WHO’s mission, thereby accelerating progress in improving survival rates and care quality for children afflicted by cancer internationally.

At the heart of this collaboration lies a fundamental conviction championed by St. Jude: a child’s geographic location must never dictate their likelihood of surviving cancer. Under the leadership of Dr. James R. Downing, St. Jude’s President and CEO, the institution actively partners with global health bodies, governments, academic institutions, and clinical providers to broaden access to comprehensive cancer care. These alliances are designed to fortify health infrastructures and knowledge exchange systems, ensuring equitable delivery of lifesaving therapies and supportive services for pediatric patients, irrespective of their origin.

St. Jude’s designation is not isolated but part of a sophisticated network of over 800 WHO collaborating centers distributed across more than 80 nations. Uniquely, St. Jude is dedicated exclusively to pediatric malignancies, making it an unparalleled resource in formulating childhood cancer policies and disseminating best practices. Since its inception as a WHO Collaborating Centre in 2018, St. Jude has leveraged its expertise to influence national health policies, boost technical capacity, and nurture multisectoral collaborations. These endeavors have collectively enhanced the global capacity to prevent, diagnose, and treat childhood cancers, shaping a more coordinated and effective response to pediatric oncology challenges.

The influence of St. Jude’s WHO Collaborating Centre extends significantly through the St. Jude Global Alliance, which encompasses over 400 institutions and foundations in more than 90 countries. This expansive network forms a robust implementation infrastructure that translates scientific discoveries into real-world improvements in pediatric cancer outcomes. As described by Dr. Catherine Lam, the Centre’s Director and a faculty clinician-scientist, this alliance fortifies the hospital’s academic and clinical expertise on an international scale, fostering innovation and knowledge transfer essential for tackling global disparities in pediatric oncology.

One of the landmark achievements stemming from this collaboration was the establishment of the WHO Global Initiative for Childhood Cancer (GICC) in 2018. This ambitious program targets a doubling of survival rates globally, aiming for at least 60% survival for childhood cancers by 2030. Complementing this, the 2025 launch of the Global Platform for Access to Childhood Cancer Medicines underscores a coordinated approach to overcoming barriers in medication availability and affordability—critical hurdles in low- and middle-income countries where cure rates have historically lagged behind.

The expanded remit of the WHO Collaborating Centre now includes not only oncology but also the management of catastrophic pediatric diseases such as sickle cell disease, representing an integrated strategy that acknowledges the complex medical and supportive care needs of these patient populations. This progression enhances the Centre’s potential to impact child health comprehensively, integrating palliative care and systems strengthening into its core objectives.

Driving the Centre’s evolving agenda, Dr. Carlos Rodriguez-Galindo, Executive Vice President and Chair of the Department of Global Pediatric Medicine, emphasizes the aim to ameliorate survival rates in regions where it has remained below 30%. Expanding the scope of pediatric care to encompass palliative services and holistic disease management initiatives ensures that children everywhere receive not only curative treatments but also dignified, comprehensive care throughout their disease trajectory.

The WHO recognizes the critical role of collaborating centers such as St. Jude in facilitating technical support, knowledge dissemination, and health system strengthening at the country level. According to Dr. Roberta Ortiz, medical officer at WHO Headquarters and focal point for the GICC, these centers bring invaluable expertise and tools that underpin successful implementation of global childhood cancer strategies. This partnership model is instrumental in translating high-level policy into practical actions that directly benefit pediatric populations.

St. Jude’s profound impact on national cancer control planning ensures that pediatric oncology is meaningfully integrated into broader health systems and governance frameworks. By embedding child-specific needs within policy platforms, the hospital advances a child-centered approach to cancer care that elevates research-driven innovations and frontline clinical breakthroughs. This comprehensive strategy enhances survivorship and quality of life for pediatric patients on a global scale.

In addition to its leadership in pediatric oncology, St. Jude also maintains a longstanding designation as a WHO Collaborating Centre for Influenza, a role it has fulfilled since 1975. This dual recognition highlights the institution’s diverse expertise and sustained contributions to global health, reaffirming its status as a vanguard institution whose research and clinical programs catalyze transformative progress across multiple domains of pediatric medicine.

St. Jude Children’s Research Hospital’s redesignation as the exclusive WHO Collaborating Centre dedicated to childhood cancer embodies the epitome of global health collaboration. Anchored in robust scientific inquiry, innovative care models, and strategic partnerships, this status propels forward a shared vision of equitable cancer care access and improved outcomes for all children—irrespective of geography. As the global pediatric oncology landscape evolves, St. Jude’s leadership and expansive alliance ensure that the journey toward eradicating childhood cancer is both scientifically rigorous and compassionately inclusive.

Subject of Research: Pediatric cancer, childhood oncology, global health collaboration

Article Title: St. Jude Reaffirmed as WHO Collaborating Centre Driving Global Pediatric Cancer Progress

News Publication Date: June 17, 2026

Web References:

• https://www.stjude.org/research/departments/global-medicine/who-collaborating-centre-for-childhood-cancer.html
• https://www.stjude.org/global/collaborating-to-cure/global-initiative.html
• https://global.stjude.org/en-us/featured/global-platform-for-access-to-childhood-cancer-medicines.html

Image Credits: St. Jude Children’s Research Hospital

Keywords: Pediatric cancer, Childhood cancer survival, WHO Collaborating Centre, Global pediatric oncology, St. Jude Global Alliance, Childhood cancer treatment access, Global Initiative for Childhood Cancer, Pediatric oncology research

In the ever-evolving landscape of biomedical research, the advent of molecular dynamics simulations has heralded a new era of insight into the dynamic behavior of biological macromolecules. Yet, despite the immense volumes of data generated by these simulations, much remains untapped due to the lack of adequate infrastructure for storage, sharing, and reuse. Addressing this critical gap, the MD4SB (Molecular Dynamics for Structure-based Biology) project emerges as a visionary initiative poised to revolutionize how molecular dynamics data is integrated, managed, and exploited across Europe.

Set to launch in September 2026, MD4SB is a collaborative endeavor funded with €10 million under the Horizon Europe program and coordinated by the Institute for Research in Biomedicine (IRB Barcelona). The project unites 25 partners spanning eight countries, encompassing academic institutions, European research infrastructures, supercomputing centers, as well as biotech and pharmaceutical companies. By doing so, it offers a multidisciplinary approach aimed at transforming fragmented computational efforts into a coherent, accessible, and reusable resource for the scientific community.

At the core of MD4SB is the establishment of an innovative infrastructure designed to dynamically describe biological macromolecules through molecular dynamics data. Unlike traditional structural biology methods that primarily capture static snapshots of molecules, molecular dynamics simulations reveal the conformational flexibility and temporal evolution of proteins and nucleic acids. This dynamic information is crucial for fully understanding molecular function, interaction mechanisms, and especially drug binding processes, thus providing a more nuanced picture for drug discovery initiatives.

MD4SB builds on the foundations laid by the Molecular Dynamics Data Bank (MDDB), which pioneered a distributed platform adhering to the FAIR principles—making data Findable, Accessible, Interoperable, and Reusable. The project advances this concept by integrating molecular dynamics data within three major European Research Infrastructures: Instruct-ERIC, which specializes in structural biology; ELIXIR, focused on life sciences data management; and EU-OPENSCREEN ERIC, a chemical biology and compound screening infrastructure. This integration ensures that molecular dynamics data becomes a shared asset rather than an isolated entity confined to individual laboratories.

Leveraging the capabilities of Europe’s largest supercomputing centers—specifically the Barcelona Supercomputing Center (BSC-CNS), CINECA in Italy, and the Jülich Supercomputing Centre (JSC)—MD4SB provides the computational muscle necessary for processing, storing, and analyzing massive datasets. These centers, combined with emerging AI Factories, will enable cutting-edge analysis pipelines that augment traditional molecular dynamics approaches with artificial intelligence, thus enhancing the extraction of biologically meaningful patterns from complex simulations.

One of the landmark objectives of MD4SB is to catalyze early drug discovery by enabling scientists to visualize the dynamic movements of proteins and other biomolecules that are often invisible in static crystal structures. Molecular dynamics simulations can reveal transient binding pockets and allosteric sites, which are pivotal for designing new therapeutic compounds with higher specificity and efficacy. By facilitating access to these insights within existing infrastructures, MD4SB aims to speed up the identification of drug candidates and reduce costly experimental failures.

Industry engagement lies at the heart of MD4SB’s strategy. Leading pharmaceutical companies such as Almirall and Sanofi are involved as associate partners, providing critical feedback to ensure that the developed platform not only serves academic research but also aligns with industrial requirements. The involvement of Nostrum Biodiscovery—a biotech spin-off from IRB Barcelona and BSC-CNS—further exemplifies the project’s commitment to bridging the gap between fundamental research and commercial application by easing the transition of innovations into practical tools.

Dr. Modesto Orozco, coordinator of MD4SB and head of the Molecular Modelling and Bioinformatics laboratory at IRB Barcelona, highlights the transformative potential of this initiative: “For the first time on a European scale, MD4SB will merge structural biology, molecular dynamics, artificial intelligence, and drug discovery into a seamless ecosystem. Our vision is to democratize molecular dynamics, making it a common capability accessible to researchers across disciplines.”

The strategic approach of MD4SB entails the seamless coupling of three complementary research infrastructures, encompassing the full spectrum of biomedical research phases: from structural protein characterization, data stewardship and interoperability, to chemical biology screening for therapeutic potentials. This holistic integration enables unprecedented collaborative workflows, where data generated in one context can be analyzed, reanalyzed, and repurposed across diverse scientific domains.

Central to the success of MD4SB will be its adherence to data standards and protocols that guarantee FAIR compliance, ensuring that the vast repositories of molecular dynamics simulations remain discoverable and usable well beyond the lifespan of individual projects. This commitment is indispensable in preventing the loss of valuable computational endeavors, promoting reproducibility, and fostering innovation driven by shared resources.

By significantly expanding the accessibility and applications of molecular dynamics data, MD4SB promises to address a longstanding bottleneck in the life sciences: the disconnect between data generation and data reuse. The project envisions a future where high-quality, large-scale molecular simulations are no longer restricted to elite research groups but are a universally available asset, fueling discoveries in biology, chemistry, and medicine.

The timeline for MD4SB spans four years, during which it will not only develop and deploy the integration platform but also benchmark its utility through real-world case studies involving both academic and industry partners. Through this collaborative validation process, the project expects to establish best practices, refine analytical tools, and build a sustainable infrastructure that institutionalizes molecular dynamics as a pillar of modern biomedical research.

In conclusion, MD4SB heralds a transformative chapter for the European research ecosystem by converging molecular dynamics with cutting-edge computational resources and artificial intelligence within a unified framework. Its success will empower scientists to decode the dynamic complexity of biological molecules at an unprecedented scale, accelerating drug discovery pipelines and fostering interdisciplinary collaboration in the era of data-driven bioscience.

---

Subject of Research: Molecular dynamics integration and infrastructure for structure-based biology, drug discovery, and biomedical research.

Article Title: MD4SB: Revolutionizing Molecular Dynamics Data Sharing and Integration Across Europe

News Publication Date: June 17, 2026

Web References:

• MD4SB project official website (to be launched)
• Horizon Europe funding portal
• IRB Barcelona: https://www.irbbarcelona.org/

Image Credits: IRB Barcelona

Keywords: Molecular dynamics, Structural biology, Supercomputing, Artificial intelligence, Drug discovery, Data infrastructure, FAIR data, Biomedical research, European Research Infrastructures, Computational biology

The global shift toward net-zero emissions has thrust hydrogen into the spotlight as a promising energy vector capable of decarbonizing sectors traditionally reliant on fossil fuels. Yet, as hydrogen technologies surge from concept to commercial reality, a critical question has emerged: can the insurance industry keep pace with the novel risks intrinsic to these systems? A compelling new article published in Engineering unveils the stark challenge facing insurers and innovators alike. It argues that the nascent nature of hydrogen processes and infrastructures presents a complex risk landscape that current insurance frameworks are ill-equipped to navigate, potentially impeding large-scale deployment needed to meet climate goals.

Central to the discourse is the intricate, multifaceted nature of hydrogen technologies, encompassing production, storage, transport, and utilization systems. Unlike mature renewable technologies such as wind and solar, hydrogen operations are fraught with unique hazards—including extreme flammability, material embrittlement due to hydrogen exposure, and elusive leakage risks—that conventional insurance models have yet to thoroughly address. This gap in risk assessment and management means that financial security mechanisms crucial for investment confidence remain underdeveloped, posing a significant barrier to scalable hydrogen adoption.

The article elucidates that hydrogen’s promise as a clean energy carrier depends not only on decarbonized production but also on scaling the entire value chain rapidly and reliably. However, these pioneering engineering systems entail a gamut of evolving operational risks. These span from property damages and equipment failures to worker safety concerns heightened by hydrogen’s explosive potential. Cybersecurity risks also arise given the increasing digitalization of energy assets, while governance challenges manifest through liability exposures of company directors as projects push technical boundaries. Furthermore, these uncertainties extend into supply chain fragility and performance shortfalls during system ramp-up phases, compounding insurers’ difficulties in crafting comprehensive coverage.

Drawing a parallel to renewable energy insurance markets, the authors observe how wind and solar have benefited from years of data accumulation, modeling refinement, and standardization efforts that underpin sophisticated insurance offerings. This data-driven maturation enables parametric insurance and warranties that safeguard against specific performance metrics and supply chain disruptions. Yet, hydrogen insurance remains embryonic, characterized by cautious underwriting and limited products chiefly targeted at niche applications rather than broad industrial deployment. This immaturity translates to cost premiums and coverage limitations that stall financing and project momentum.

To transcend these hurdles, the article emphasizes the critical need for structured data collection and robust risk characterization specific to hydrogen processes. Without granular operational insights and validated risk models, insurers default to conservative stances that restrict underwriting appetite. The authors champion innovative insurance instruments, notably parametric policies calibrated to predefined risk triggers, and performance warranties that hedge against technology underperformance. These solutions can lower uncertainty for investors and catalyze capital flow, but their success hinges on collaborative data-sharing and transparent risk communication between all stakeholders.

Importantly, the narrative draws attention to a strategic opportunity for insurers. Engagement with hydrogen not only mitigates climate-related portfolio risks but also opens access to a burgeoning industrial market driven by global net-zero ambitions. Nonetheless, disconnects persist between technology developers’ needs and insurers’ capabilities, underscoring the urgency for proactive, multi-stakeholder dialogue. Fostering early-stage collaboration among engineers, academia, private sector, and insurance providers is pivotal to co-design risk assessment methodologies, standardize certification regimes, and ultimately align insurance solutions with engineering innovation trails.

Academia is positioned as a critical catalyst in this ecosystem. Researchers can bridge the gap by aggregating operational data, refining risk models via simulations and real-world studies, and facilitating standardization efforts that underpin insurer confidence. Such integrative efforts advance both scientific understanding and commercial viability. Aligning insurance mechanisms with engineering innovation timelines ensures risk management is embedded from technology readiness level milestones onward, thus streamlining the pathway from pilot projects to full-scale industrial rollouts.

The article also highlights the financial repercussions of currently inadequate insurance coverage. High premiums and coverage gaps retard investment flows and engender hesitancy among financiers wary of unquantified risks. As hydrogen projects are capital-intensive with long development horizons, risk mitigation via comprehensive insurance is non-negotiable for unlocking broader investor appetite. Hence, the advancement of hydrogen insurance products is not merely a financial instrument but a keystone for sustainable market adoption and technological acceleration.

Furthermore, the article delves into technical challenges such as hydrogen’s propensity to induce embrittlement in metals, which degrades structural integrity over time and raises maintenance costs. Insurance models must incorporate such materials science insights to accurately price and cover long-term durability risks. Leakage detection and mitigation technologies also play a vital role in controlling operational hazards, with insurance frameworks incentivizing advancements in sensor deployment and safety protocols. These technological synergies between engineering and insurance amplify resilience and facilitate risk reduction.

In conclusion, the article contends that unlocking hydrogen’s potential as a linchpin of a net-zero future demands a paradigm shift in insurance thinking coupled with systemic collaboration. By gathering rigorous data, designing bespoke risk instruments, and fostering cross-sector partnerships, the insurance market can evolve to support hydrogen innovation robustly. This evolution will serve as the linchpin of investor confidence, enabling swift scale-up while safeguarding public and environmental safety. Without such advancements, the hydrogen economy risks stalling, imperiling global decarbonization trajectories.

The implications extend beyond risk transfer to the very architecture of hydrogen energy systems. Insurance integration informs engineering decisions, safety standards, and policy frameworks, creating a virtuous cycle that harmonizes technical innovation with financial viability. The authors’ clarion call is clear: accelerating the hydrogen transition mandates bridging the gap between emergent technology risks and insurance market readiness. Achieving this nexus will be transformative—not only for hydrogen but for the broader energy transition imperative writ large.

Subject of Research: Insurance frameworks and risk management for new hydrogen technologies and adapted hydrogen processes.

Article Title: Insurance for New and Adapted Hydrogen Processes

News Publication Date: 15-Apr-2026

Web References:
https://doi.org/10.1016/j.eng.2025.11.018
https://www.sciencedirect.com/journal/engineering

Image Credits: Elisabeth Shrimpton, Nazmiye Balta-Ozkan

Keywords: Hydrogen, Net-Zero Energy Transition, Insurance, Risk Management, Engineering Innovation, Parametric Insurance, Performance Warranty, Material Embrittlement, Hydrogen Safety, Technology Readiness, Energy Decarbonization, Financial Instruments

The IPO market is back, and it’s not the same companies leading the charge. FAANG had a good run, but a new acronym is taking over: MANGOS — Meta (or Microsoft, depending on who you ask), Anthropic, Nvidia, Google, OpenAI, and SpaceX. Half of that bunch is heading to public markets in the same window, and it’s a stress test for investors, for valuations, and for […]

Cursor will open its European headquarters in London and expand its EMEA workforce as demand grows for AI coding tools.

Indigenous Peoples in Voluntary Isolation and Initial Contact (PIACI) in the Yavarí-Tapiche Territorial Corridor, one of the largest contiguous, intact forests in the Amazon and home to the world’s highest concentrations of PIACI, are under threat by extractive and large-scale industrial activities, which pose an existential threat to its inhabitants and the ecosystems they depend on. This is according to a new report co-authored by Earth Insight, the Regional Organization of Indigenous Peoples of the East (ORPIO), the Coordination of the Indigenous Organizations of the Brazilian Amazon (COIAB) and the Interethnic Association for the Development of the Peruvian Rainforest (AIDESEP). The report finds that oil and gas blocks overlap with 10% of the 16-million-hectare (39.5-million-acre) corridor, including almost 1.7 million hectares (4.2 million acres) of intact tropical moist forest, 907,000 hectares (2.2 million acres) of Key Biodiversity Areas and 713,000 hectares (1.8 million acres) of protected areas. “Pressure from hydrocarbons is increasing on the Peruvian side of the Yavarí Tapiche corridor,” Edith Espejo, senior program manager at Earth Insight and author of the report, told Mongabay over WhatsApp messages. “Our report serves as a warning for the irreversible harm that could take place if these oil blocks move into this corridor. Mining concessions within and on the peripheries of the corridor also pose a threat of encroachment and contamination of waterways.” A critical corridor for ecosystems and Indigenous communities The Yavarí-Tapiche Corridor covers Brazil’s western border states of Amazonas and Acre and Peru’s Loreto and Ucayali departments in the Amazon…This article was originally published on Mongabay